Holen Sie sich die Stockscreener-App
1.35
10.60%
-0.16
Handel nachbörslich:
1.34
-0.01
-0.74%
Schlusskurs vom Vortag:
$1.51
Offen:
$1.41
24-Stunden-Volumen:
169.00K
Relative Volume:
1.22
Marktkapitalisierung:
$35.10M
Einnahmen:
$2,000
Nettoeinkommen (Verlust:
$-9.12M
KGV:
-3.4678
EPS:
-0.3893
Netto-Cashflow:
$-3.35M
1W Leistung:
-28.95%
1M Leistung:
+13.45%
6M Leistung:
-35.71%
1J Leistung:
-65.99%
1-Tages-Spanne:
$1.2205
$1.4878
1-Wochen-Bereich:
$1.2205
$2.15
52-Wochen-Spanne:
$0.8801
$4.045
Abvc Biopharma Inc Stock (ABVC) Company Profile
Firmenname
Abvc Biopharma Inc
Sektor
Branche
Telefon
510-668-0881
Adresse
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
1.35 | 39.26M | 2,000 | -9.12M | -3.35M | -0.3893 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Abvc Biopharma Inc Aktie (ABVC) Neueste Nachrichten
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language - Stock Titan
Price to sales forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Price to book forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
ABVC Should I Buy - Intellectia AI
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC) - TradingView
ABVC Q1 2025 Earnings: EPS of -0.06 Reflects Ongoing R&D Investment; Stock Gains 2.82%Earnings Yield Spread - dars.gov.et
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - 富途牛牛
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Net Loss of $0.06 Per Share as Stock Rises 1.53% Amid No Reported RevenueForward Guidance Trends - dars.gov.et
ABVC BioPharma to Spin Off BioKey Subsidiary via Dividend Distribution to Shareholders - MEXC
ABVC Q1 2025 Earnings: Clinical-Stage Biotech Reports Net Loss as Pipeline Efforts ContinueLong-Term Guidance - DonanımHaber
ABVC Q1 2025 Earnings: Loss Per Share of -$0.06 as Clinical Pipeline ProgressesBook Value Growth - dars.gov.et
ABVC Biopharma Inc (ABVC) Institutional Confidence - TradingKey
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressLow Estimate Range - dars.gov.et
ABVC Q1 2025 Earnings: No Revenue Reported, EPS Loss of -$0.06 Amid Ongoing R&D FocusEarnings Call Highlights - DonanımHaber
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical DevelopmentReturn On Capital - dars.gov.et
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC - Finviz
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
TradingKey - TradingKey
How sustainable is BioPharma (ABVC) profit margins? (Institutional Selling) 2026-05-08MACD Signals - newser.com
Finanzdaten der Abvc Biopharma Inc-Aktie (ABVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.60%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):